TDT 044
Treatment of Steroid Responsive Skin Conditions
TDT-044 is using Transfersome® carriers to deliver corticosteroids for better treatment of dermatoses including psoriasis and eczema.
Psoriasis is an auto-immune disease involving skin inflammation and causing psoriatic plaques. It affects around 2-3% of the population, who are typically treated by topical mid and high potency steroids. Such treatments are limited by the skin atrophying side effects of steroids, however, calling strongly for a safer steroid treatment.
TDT-044 is being developed to achieve a similar effect as the effect of current high potency steroids, but using lower drug dosages and permitting longer treatment, thus significantly improving patients' quality of life.
Market
In addition to higher-potency steroids, a variety of powerful and expensive systemic agents are used to treat the more severe psoriasis patient. These include injected anti-TNF antibodies, oral cyclosporin, and other systemic immunosuppressants. All of these drugs have medium to severe side effects associated with systemic drug presence. The market size for high-potency steroids is approximately $500 million annually. Successfully accessing the medium-potency market, by delivering the intended product profile, could significantly expand the potential market value.